Xenoport Inc (XNPT) 3.64 $XNPT
Hot Stock: XenoPort, Shares Drop 8.2% (XNPT)
Comtex SmarTrend(R) - Fri May 09, 12:44PM CDT
XenoPort (NASDAQ:XNPT) is one of today's worst performing low-priced stocks, down 8.2% to $3.29 on 1.1x average daily volume. Thus far today, XenoPort has traded 510,000 shares, vs. average volume of 454,000 shares per day. The stock has underperformed the Dow (-8.2% to the Dow's 0.1%) and underperformed the S&P 500 (-8.2% to the S&P's 0.0%) during today's trading.
XenoPort to Mail Letter to Stockholders
Business Wire - Fri May 09, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) today announced that it is mailing a letter to stockholders in connection with the Company's upcoming Annual Meeting, which will be held on June 11, 2014.
XenoPort Reports First Quarter Financial Results
Business Wire - Thu May 08, 3:10PM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the first quarter ended March 31, 2014. Revenues for the quarter were $3.4 million, compared to $0.5 million for the same period in 2013. Net loss for the first quarter was $20.5 million, compared to a net loss of $23.5 million for the same period in 2013. At March 31, 2014, XenoPort had cash and cash equivalents and short-term investments of $122.5 million.
Is a Surprise Coming for Xenoport (XNPT) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:30AM CDT
Xenoport (XNPT) is poised to beat at earnings season. That is because Xenoport is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:00PM CDT
Perrigo (PRGO) is set to report third quarter fiscal 2014 results on May 7 before the market opens.
XenoPort to Release First Quarter Financial Results on May 8, 2014
Business Wire - Thu May 01, 9:01AM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its first quarter financial results on May 8, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
XenoPort Presents New Analyses of Data for Gabapentin Enacarbil at the 33rd Annual Scientific Meeting of the American Pain Society
Business Wire - Wed Apr 30, 7:31AM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present new analyses of data for gabapentin enacarbil (GEn), the active ingredient in HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets, at the 33rd Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Clinton Group Announces Availability of Definitive Proxy Materials for XenoPort Annual Meeting
PR Newswire - Fri Apr 25, 10:49AM CDT
Clinton Group, Inc. announced today that its definitive proxy materials for the XenoPort, Inc. (Nasdaq: XNPT) annual meeting are available. The meeting is scheduled for June 11, 2014.
XenoPort to Present New Data for Novel Fumarate Analog XP23829 and HORIZANT at the 66th Annual Meeting of the American Academy of Neurology
Business Wire - Thu Apr 24, 7:31AM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present data on its investigational and marketed therapies for neurological diseases at the 66th Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829, an investigational prodrug of monomethyl fumarate (MMF). XP23829 is currently being evaluated as a potential treatment for moderate-to-severe chronic plaque type psoriasis and may be a potential treatment for relapsing forms of multiple sclerosis (MS).
Why XenoPort Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XenoPort , a biopharmaceutical company...
XenoPort Files Definitive Proxy Materials and Mails Letter to Stockholders
Business Wire - Tue Apr 22, 7:31AM CDT
XenoPort, Inc. (Nasdaq: XNPT) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with the Company's 2014 Annual Meeting of Stockholders. Clinton Relational Opportunity Master Fund L.P. and its affiliates ("Clinton"
, which reportedly hold approximately 1.8% of the Company's common stock, have provided notice of their intent to nominate three candidates to stand for election to XenoPort's Board of Directors and to submit other proposals for consideration at the Annual Meeting.
XenoPort Has Returned 9.3% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Fri Mar 28, 10:05AM CDT
SmarTrend identified a Downtrend for XenoPort (NASDAQ:XNPT) on February 3rd, 2014 at $5.73. In approximately 2 months, XenoPort has returned 9.34% as of today's recent price of $5.19.
XenoPort Earnings In Retrospect: Down 0.3% in the Last 18 Days (XNPT)
Comtex SmarTrend(R) - Mon Mar 10, 7:55AM CDT
When XenoPort (NASDAQ:XNPT) reported earnings 18 days ago on February 20th, 2014, analysts, on average, expected the company to report a loss of $0.48 on sales of $3.8 million. XenoPort actually reported a loss of $0.40 per share on sales of $2.9 million, beating EPS estimates by $0.08 and missing revenue estimates by $0.9 million. Shares of XenoPort have slipped from $5.89 to $5.87, representing a loss of 0.3%, since the company reported earnings 18 days ago.
ESI to Present at Two March Investor Conferences
Business Wire - Tue Mar 04, 7:55AM CST
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including:
XenoPort to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 9:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Cowen and Company 34th Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 5, 2014. A replay of the presentation will also be available.
XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:22AM CST
XenoPort's loss narrows in fourth quarter of 2013.
XenoPort Reports Fourth Quarter and Year-End 2013 Financial Results
Business Wire - Thu Feb 20, 3:05PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited (GSK) in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
Hot Stock: XenoPort, Shares Drop 8.2% (XNPT)
Comtex SmarTrend(R) - Fri May 09, 12:44PM CDT
XenoPort (NASDAQ:XNPT) is one of today's worst performing low-priced stocks, down 8.2% to $3.29 on 1.1x average daily volume. Thus far today, XenoPort has traded 510,000 shares, vs. average volume of 454,000 shares per day. The stock has underperformed the Dow (-8.2% to the Dow's 0.1%) and underperformed the S&P 500 (-8.2% to the S&P's 0.0%) during today's trading.
XenoPort to Mail Letter to Stockholders
Business Wire - Fri May 09, 7:30AM CDT
XenoPort, Inc. (Nasdaq:XNPT) today announced that it is mailing a letter to stockholders in connection with the Company's upcoming Annual Meeting, which will be held on June 11, 2014.
XenoPort Reports First Quarter Financial Results
Business Wire - Thu May 08, 3:10PM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today its financial results for the first quarter ended March 31, 2014. Revenues for the quarter were $3.4 million, compared to $0.5 million for the same period in 2013. Net loss for the first quarter was $20.5 million, compared to a net loss of $23.5 million for the same period in 2013. At March 31, 2014, XenoPort had cash and cash equivalents and short-term investments of $122.5 million.
Is a Surprise Coming for Xenoport (XNPT) This Earnings Season? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu May 08, 7:30AM CDT
Xenoport (XNPT) is poised to beat at earnings season. That is because Xenoport is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.
Will Regeneron (REGN) Disappoint in Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed May 07, 4:20PM CDT
Regeneron (REGN) is set to report its first quarter 2014 results on Feb 8 before the opening bell.
Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014: 23 Companies and 33 Drugs Profiled
M2 - Wed May 07, 12:10PM CDT
Research and Markets (http://www.researchandmarkets.com/research/p7dbhq/relapsing) has announced the addition of the "Relapsing Remitting Multiple Sclerosis (RRMS) - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsing Remitting Multiple Sclerosis (RRMS) and special features on late-stage and discontinued projects. The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Companies Involved in Therapeutics Development - AbbVie Inc. - Actelion Ltd - Allozyne, Inc. - Amarna Therapeutics B.V. - Biogen Idec Inc. - Cognosci, Inc. - Eli Lilly and Company - F. Hoffmann-La Roche Ltd. - Genmab A/S - GlaxoSmithKline plc - MedImmune, LLC - Merck KGaA - Mitsubishi Tanabe Pharma Corporation - Neurotec Pharma SL - Novartis AG - Nuron Biotech, Inc. - Opexa Therapeutics, Inc. - Receptos, Inc. - RedHill Biopharma Ltd. - Synthetic Biologics, Inc. - Teva Pharmaceutical Industries Limited - Trophos SA - XenoPort, Inc. Drug Profiles: - laquinimod sodium - dimethyl fumarate - laquinimod sodium - fingolimod hydrochloride - ocrelizumab - interferon beta-1b - daclizumab - RPC-1063 - Epigallocatechin Gallate - GSK-239512 - siponimod - tabalumab - firategrast - ponesimod - plovamer acetate - estriol - imilecleucel-t - olesoxime - ofatumumab - RNS-60 - (rifabutin clarithromycin clofazimine) - diazoxide - MT-1303 - Boswellic Acids - VAY-736 - MEDI-551 - interferon beta-1b pegylated - XP-23829 - Pegylated Interferon-Beta-1b - COG-133 For more information visit http://www.researchandmarkets.com/research/p7dbhq/relapsing
Is Perrigo (PRGO) Poised to Beat Earnings Estimates? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue May 06, 4:00PM CDT
Perrigo (PRGO) is set to report third quarter fiscal 2014 results on May 7 before the market opens.
XenoPort to Release First Quarter Financial Results on May 8, 2014
Business Wire - Thu May 01, 9:01AM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will release its first quarter financial results on May 8, 2014 at approximately 4:30 p.m. Eastern Time. The company will host a conference call at 5:00 p.m. Eastern Time that same day. A replay of the call will be available for one week following the event.
XenoPort Presents New Analyses of Data for Gabapentin Enacarbil at the 33rd Annual Scientific Meeting of the American Pain Society
Business Wire - Wed Apr 30, 7:31AM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present new analyses of data for gabapentin enacarbil (GEn), the active ingredient in HORIZANT(R) (gabapentin enacarbil) Extended-Release Tablets, at the 33rd Annual Scientific Meeting of the American Pain Society (APS) in Tampa, Florida.
Global Dyskinesia Therapeutic Pipeline Review 2014
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/wks94f/dyskinesia) has announced the addition of the "Global Dyskinesia Therapeutic Pipeline Review 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Dyskinesia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Dyskinesia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Dyskinesia - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Dyskinesia and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects Companies Involved in Therapeutics Development - XenoPort, Inc. - Novartis AG - BioMarin Pharmaceutical Inc. - Addex Therapeutics - Avanir Pharmaceuticals, Inc. - NeuroSearch A/S - Catalyst Pharmaceutical Partners, Inc. - Neurim Pharmaceuticals Ltd - Santhera Pharmaceuticals Holding AG - Upsher-Smith Laboratories, Inc. - Adamas Pharmaceuticals, Inc. - Targacept, Inc. - Heptares Therapeutics Ltd. - Amarantus Bioscience Holdings, Inc. - SciFluor Life Sciences, LLC - SK Biopharmaceuticals Co., Ltd. - Merz Pharmaceuticals GmbH - Neurolixis Inc. - Contera Pharma ApS Drug Profiles - amantadine hydrochloride - AQW-051 - dipraglurant - eltoprazine - fipamezole - (dextromethorphan hydrobromide quinidine sulfate) - JM-010 - Neu-120 - ordopidine - SKL-PD - befiradol - naluzotan - CPP-115 - Acamprosate Prodrug - Neu-240 - MRZ-8676 - RGFP-109 - TC-8831 - NLX-112 - IRL-790 - Movement Disorders Program - Drug to Inhibit Dyskinesia and Hyperkinetic Movement Disorders - Small Molecule Targeting mGluR5 - Small Molecule For Dyskinesia - Small Molecules To Antagonise Metabotropic Glutamate Receptor 5 (mGluR5) For Dyskinesia For more information visit http://www.researchandmarkets.com/research/wks94f/dyskinesia
Clinton Group Announces Availability of Definitive Proxy Materials for XenoPort Annual Meeting
PR Newswire - Fri Apr 25, 10:49AM CDT
Clinton Group, Inc. announced today that its definitive proxy materials for the XenoPort, Inc. (Nasdaq: XNPT) annual meeting are available. The meeting is scheduled for June 11, 2014.
XenoPort to Present New Data for Novel Fumarate Analog XP23829 and HORIZANT at the 66th Annual Meeting of the American Academy of Neurology
Business Wire - Thu Apr 24, 7:31AM CDT
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will present data on its investigational and marketed therapies for neurological diseases at the 66th Annual Meeting of the American Academy of Neurology (AAN) in Philadelphia. Data being presented include the results from a clinical trial evaluating the safety, tolerability and pharmacokinetics of XP23829, an investigational prodrug of monomethyl fumarate (MMF). XP23829 is currently being evaluated as a potential treatment for moderate-to-severe chronic plaque type psoriasis and may be a potential treatment for relapsing forms of multiple sclerosis (MS).
Why XenoPort Inc. Shares Popped
Sean Williams, The Motley Fool - Motley Fool - Tue Apr 22, 1:09PM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of XenoPort , a biopharmaceutical company...
XenoPort Files Definitive Proxy Materials and Mails Letter to Stockholders
Business Wire - Tue Apr 22, 7:31AM CDT
XenoPort, Inc. (Nasdaq: XNPT) today announced that it has filed definitive proxy materials with the Securities and Exchange Commission in connection with the Company's 2014 Annual Meeting of Stockholders. Clinton Relational Opportunity Master Fund L.P. and its affiliates ("Clinton"
, which reportedly hold approximately 1.8% of the Company's common stock, have provided notice of their intent to nominate three candidates to stand for election to XenoPort's Board of Directors and to submit other proposals for consideration at the Annual Meeting. XenoPort Has Returned 9.3% Since SmarTrend Recommendation (XNPT)
Comtex SmarTrend(R) - Fri Mar 28, 10:05AM CDT
SmarTrend identified a Downtrend for XenoPort (NASDAQ:XNPT) on February 3rd, 2014 at $5.73. In approximately 2 months, XenoPort has returned 9.34% as of today's recent price of $5.19.
XenoPort Earnings In Retrospect: Down 0.3% in the Last 18 Days (XNPT)
Comtex SmarTrend(R) - Mon Mar 10, 7:55AM CDT
When XenoPort (NASDAQ:XNPT) reported earnings 18 days ago on February 20th, 2014, analysts, on average, expected the company to report a loss of $0.48 on sales of $3.8 million. XenoPort actually reported a loss of $0.40 per share on sales of $2.9 million, beating EPS estimates by $0.08 and missing revenue estimates by $0.9 million. Shares of XenoPort have slipped from $5.89 to $5.87, representing a loss of 0.3%, since the company reported earnings 18 days ago.
ESI to Present at Two March Investor Conferences
Business Wire - Tue Mar 04, 7:55AM CST
Electro Scientific Industries, Inc. (NASDAQ: ESIO), a leading supplier of innovative laser-based manufacturing solutions for the microtechnology industry, today announced it will be participating at two upcoming investor conferences, including:
XenoPort to Present at the Cowen and Company 34th Annual Health Care Conference
Business Wire - Mon Feb 24, 9:00AM CST
XenoPort, Inc. (Nasdaq: XNPT) announced today that it will provide access via the World Wide Web to its presentation at the 2014 Cowen and Company 34th Annual Health Care Conference. The live presentation will occur at 7:40 a.m. Pacific Time (10:40 a.m. Eastern Time) on Wednesday, March 5, 2014. A replay of the presentation will also be available.
XenoPort's 4Q Loss Narrower-Than-Expected - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 10:22AM CST
XenoPort's loss narrows in fourth quarter of 2013.
XenoPort Reports Fourth Quarter and Year-End 2013 Financial Results
Business Wire - Thu Feb 20, 3:05PM CST
XenoPort, Inc. (Nasdaq:XNPT) announced today its financial results for the fourth quarter and year ended December 31, 2013. Revenues for the fourth quarter were $2.9 million, compared to $0.5 million for the same period in 2012. Net loss for the fourth quarter was $19.1 million compared to net income of $3.0 million that resulted from a non-cash gain from XenoPort's litigation settlement with Glaxo Group Limited (GSK) in the fourth quarter of 2012. At December 31, 2013, XenoPort had cash and cash equivalents and short-term investments of $58.7 million.
